N-(n-Butyl)deoxygalactonojirimycin
(Synonyms: N-(正丁基)脱氧半乳糖霉素,NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin) 目录号 : GC41235
An inhibitor of glucosylceramide synthase, glucocerebrosidase, and β-glucosidase 2
Cas No.:141206-42-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
N-(n-Butyl)deoxygalactonojirimycin is an inhibitor of α-D-galactosidase. It has also been shown to prevent glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders by inhibiting the ceramide-specific glucosyltransferase, UDP-glucose ceramide glucosyltransferase (IC50 = 41.4 µM) without affecting α-glucosidase I and II or β-glucocerebrosidase (IC50s > 1 mM). This compound has been used to sensitize cultured chronic lymphocytic leukemia cells to the chemotherapeutic agents cladribine , chlorambucil , and fludarabine .
| Cas No. | 141206-42-0 | SDF | |
| 别名 | N-(正丁基)脱氧半乳糖霉素,NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin | ||
| Canonical SMILES | OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@H]1O | ||
| 分子式 | C10H21NO4 | 分子量 | 219.3 |
| 溶解度 | DMF: 20 mg/mL,DMSO: 30 mg/mL,Ethanol: 5 mg/mL,PBS (pH 7.2): 10 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.56 mL | 22.7998 mL | 45.5996 mL |
| 5 mM | 0.912 mL | 4.56 mL | 9.1199 mL |
| 10 mM | 0.456 mL | 2.28 mL | 4.56 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Novel method for chase analysis of oligosaccharide metabolic error caused by xenobiotics
Anal Biochem 2010 Oct 1;405(1):103-8.PMID:20570645DOI:10.1016/j.ab.2010.06.002.
Saccharide primers, such as dodecyl beta-lactoside (Lac-C12), are unique artificial precursors of glycolipid synthesis. In culture media supplemented with saccharide primers, they are taken up by the cells in the culture media and glycosylated by cellular glycosyltransferases in the Golgi apparatus to form pseudo-glycolipids. In this study, we examine the effects of various xenobiotics on glycolipid synthesis by implementing a novel method to analyze pseudo-glycolipids, mainly gangliosides, produced by ONS-76 medulloblastoma cells in a culture medium containing various xenobiotics. The ganglioside group of pseudo-glycolipids was effectively purified by using strong anion-exchange cartridges. The production of pseudo-gangliosides was stimulated by N-(n-Butyl)deoxygalactonojirimycin (NB-DGJ), but was inhibited by castanospermine, 2-deoxy-2-fluoro-d-galactose, tunicamycin, and brefeldin A. Because the cells in the culture medium are exposed to the saccharide primers and xenobiotics at the same time, and are secreted in the culture medium in their glycosylated form, our method can be used to effectively analyze the direct effects of xenobiotics on ganglioside synthesis.